It’s time to take on your
enlarged prostate (BPH).

Learn about a new, no cost research study for BPH
involving the UroLift ® System Treatment.

Benign Prostatic Hyperplasia, or BPH, is a condition in which the prostate enlarges as men get older. BPH is very common - in fact, over 40% of men in their 50’s and over 70% of men in their 60’s have BPH.1 As the prostate enlarges, it presses on and blocks the urethra, causing bothersome urinary symptoms such as:

  • Frequent need to urinate both day and night
  • Weak or slow urinary stream, and/or a stream that stops and starts
  • A sense that you cannot completely empty your bladder
  • Urgent feeling of needing to urinate

While prostate surgery is an option for some, these procedures often require general anesthesia and can also cause long-term side effects such as sexual dysfunction and urinary incontinence.

If you’re living with BPH and are interested in exploring non-surgical treatment options, you may qualify for the IMPACT Clinical Study. The study involves the UroLift® System treatment, an FDA-cleared device designed to relieve BPH symptoms through a simple outpatient procedure.

What is the UroLift® System?

The prostate is about the size of a walnut, and is located at the neck of the bladder. For most men, starting around age 40 their prostate begins to grow, and if it becomes large enough, the enlarged prostate can put pressure on the urethra, the tube that carries urine out of the body. This pressure blocks the natural flow of urine, causing uncomfortable symptoms and irritation.

The UroLift® System is a revolutionary approach to treating BPH that lifts and holds the enlarged prostate tissue so it no longer blocks the urethra. Treatment with the UroLift System is typically a one-time, in-office solution that does not involve heating, cutting, or removal of the prostate tissue, allowing patients to return home the same day.2



What is the IMPACT Study?

The UroLift System is currently being offered at no cost at select US centers through the IMPACT Clinical Study. As part of the study, participants will have a 50/50 chance of initially having the UroLift System treatment, or taking an FDA-approved BPH medication (tamsulosin) for 3 months. If you are part of the group that initially receives the BPH medication, you will have the option after 3 months to receive the UroLift System treatment at no cost to you.

Following the UroLift System treatment, you will meet with your study doctor up to 4 times over a 1-year period to evaluate your progress. You may also be compensated for your time and travel to attend these visits.

See If You Qualify

To see if you might qualify for the IMPACT Clinical Study, and to get connected with your local study center to learn more, please take the pre-screening questionnaire below:


  1. Berry, et al., Journal of Urology 1984
  2. Roehrborn, J Urol 2013, L.I.F.T. Study